Aligos Therapeutics, Inc. ALGS
5.51
(0.04)
(0.72%)
as of 25 Sep
- Market cap
- $32.6M
- P/E
- 0.0×
Follow ALGS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
38.41 | 42.14 | 16.43 | 1.91 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.17) | (4.24) | (3.34) | (2.41) | |
P/B ratio |
1.41 | 1.72 | 2.43 | 1.89 | |
Price to Tangible BV |
1.41 | 1.72 | 2.43 | 1.89 | |
EV/Sales |
0.96 | 6.54 | 4.75 | 0.95 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.03) | (0.17) | (0.26) | (0.32) | |
EV/FCF |
(0.03) | (0.17) | (0.26) | (0.32) | |
Quick Ratio |
4.51 | 3.67 | 2.36 | 2.05 | |
Current Ratio |
4.70 | 3.90 | 2.56 | 2.19 | |
Net Debt/EBITDA |
3.61 | 3.33 | 2.04 | 17.82 | |
Debt/Assets |
0.11% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.03 | 0.04 | 0.31 | |
Operating CF/Net income |
0.77 | 1.09 | 1.00 | 16.59 | |
Capex/Depreciation |
(0.22) | 0.06 | 0.95 | (0.01) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3,230.36% | 10,081.66% | 825.16% | 86.58% | |
Selling, General and Administrative Expense of Revenue |
697.03% | 2,926.04% | 226.40% | 20.22% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
197.98% | 862.72% | 46.43% | 4.91% | |
Graham Net Nets |
0.64 | 0.52 | 0.35 | 0.46 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(127.86%) | (14.59%) | (116.96%) | (126.52%) | |
Free Cash Flow Yield |
(78.27%) | (90.03%) | (110.21%) | (157.05%) | |
Revenue per Share |
0.07 | 0.02 | 0.27 | 2.66 | |
Operating CF per Share |
(2.35) | (2.20) | (2.22) | (2.39) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(2.37) | (2.21) | (2.23) | (2.39) | |
Cash per Share |
9.57 | 7.89 | 5.29 | 2.92 | |
Shareholders Equity per Share |
6.93 | 5.42 | 3.06 | 3.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.93 | 5.42 | 3.06 | 3.06 | |
Free Cash Flow |
(24.54) | (21.84) | (23.20) | (24.95) | |
Working Capital |
81.45 | 61.63 | 36.31 | 33.78 | |
Capital Expenditures |
(0.19) | (0.09) | (0.07) | 0.00 | |
Net Current Asset Value |
65.50 | 47.87 | 26.86 | 27.68 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.26 | 0.54 | 0.02 | 0.00 | |
Net Profit Margin |
(4,256.01%) | (11,763.91%) | (814.13%) | (5.41%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.70 | 3.28 | 6.05 | 5.18 | |
Average Assets |
99.10 | 79.31 | 107.63 | 100.52 | |
Average Common Equity |
60.96 | 12.29 | 74.12 | 66.87 |
Columns are period end dates